WHO sets goals for future long-acting TB injections
WHO sets goals for future long-acting TB injections
Updated at: October 30, 2026 at 01:08 AM
Taking medicine every day for months can be difficult. WHOโs October 28 update describes development goals for long-acting injectable regimens against tuberculosis. The document guides future research; it does not announce that these proposed regimens are already available for routine use.
The profiles distinguish prevention from treatment of TB disease. For preventive treatment, the goal is a complete course delivered through one injection at one encounter. That is a design target, not a direction for patients to change existing medicines.
For TB disease, the profile aims for a regimen lasting no more than four months, with three or fewer dosing encounters. The number of visits and the treatment duration are separate characteristics that developers must consider together.
Convenience is not the only requirement. The profiles seek efficacy and safety at least as good as current oral regimens, small injection volumes and delivery by trained health workers. They also call for products that do not require a cold chain.
Each characteristic has a minimum requirement and an optimal target. The framework also considers costs, access and the burden on health services. Fewer patient dosing encounters still require a system capable of delivering them reliably.
Patient choice remains important. WHO says work on better oral regimens should continue alongside injectable development. The purpose is to create useful alternatives, rather than assume that every person would prefer an injection.
